ellansé physicians brochure
Post on 26-Jul-2016
235 Views
Preview:
DESCRIPTION
TRANSCRIPT
Regenerate BeautyThrough Collagen Stimulation
W288.01
W288.02-ELLANSE Physicians Brochure_vA01.indd 1 2/02/2016 10:42 am
2
Bone
resorptio
n
& remod
eling Fat loss
& redistribution
Dermal aging
collagen lossMus
cle to
ne
and atroph
y
Facial aging is a multifactorial process that affects different layers.
Muscle Tone & Atrophy
• Facial muscles become more tensed and atrophic
• Contribute to facial sagging and droopiness
• Fat pads displacement
Bone Resorption & Remodeling
AGE
• Significant loss of facial bone with age4
• Leads to biometric volume loss2-4
• Noticeable changes in the other layers of overlying soft tissue and skin1,3
Fat Loss & Redistribution
• Fat pads loss and/or migration under muscular action leading to deep creases and contour defects1-6
• Accumulation of fat in some areas (e.g. under the lower eyelid, jaw, mouth) leading to the impression of permanent puffiness
Facial Aging Process
W288.02-ELLANSE Physicians Brochure_vA01.indd 2 2/02/2016 10:42 am
3
Dermal Aging & Collagen Loss
As the aging skin loses its structural proteins (collagen and elastin), it becomes more lax and begins to sag, which contributes to a tired and aged look.
Collagen Modifications with Aging
• Decrease in the level of collagen
• Changes in histological characteristics (collagen fibers distribution)
• Changes in ultrastructure (collagen network disorganization)
• Fragmentation of fibrils, fibroblast can no longer bind
Collagen in youthful skin
EPIDERMIS
DERMIS
SUBCUTANEOUSLAYER
CollagenProvides infrastructure for elastin and hyaluronic acid
ElastinHelps the skin retain its elasticity
Hyaluronic AcidWater binds to hyaluronic acid, keeping the skin moist
Well structured collagennetwork7
Collagen loss in aging skin
DERMIS
SUBCUTANEOUSLAYER
EPIDERMIS
Collagen networkdisorganization7
Decreased Collagen
Decreased Hyaluronic Acid
Decreased Elastin
W288.02-ELLANSE Physicians Brochure_vA01.indd 3 2/02/2016 10:42 am
4
ELLANSÉTM : A tailor-made bioresorbable collagen stimulator8
Composition
• Totally smooth polycaprolactone (PCL) microspheres 25-50 μm
• PBS*-based carboxymethylcellulose (CMC) gel-carrier
PCL & CMC
• Excellent safety profile and largely used in bioresorbable implants (sutures and orthopedic implants dermal fillers, oral and maxillo-facial surgery) for several decades worldwide
• Used in numerous European (CE-certified) and US Food and Drug Administration (FDA) approved commercial bioresorbable products in cosmetic and pharmaceutical industries Totally smooth
polycaprolactone (PCL)PCL microspheres homogenously
suspended in a PBS*-based carboxymethylcellulose CMC gel-carrier
STATTM Technology : A Unique Manufacturing Process with Several Benefits
STAT TM
Technology
Sustained Performance, Tunable Longevity And Total Bioresorbability
• Maintained correction over total duration of effect through one single injection
• Different levels of action depending on patients' needs
• Fully resorbable treatment with a predictable, controlled and tunable bioresorption and a high safety profile
These 3 features give ELLANSÉTM unique advantages
PCL
30% 70%
CMCGel carrier
*(Phosphate Buffered Saline)
W288.02-ELLANSE Physicians Brochure_vA01.indd 4 2/02/2016 10:42 am
5
ELLANSÉTM is an injectable implant, indicated for sub-dermal implantation, for the lasting correction of wrinkles and other connective tissue imperfections or conditions.
• Medical Device Class III8
• CE mark obtained in 2009
• Distributed in more than 80 countries
ELLANSÉTM comes in ready-to-use syringes:
• 2 x 1 ml syringes of ELLANSÉTM with 4 x 27G 3/4" needles
• 2 x 0.5 ml syringes of ELLANSÉTM with 4 x 27G 3/4" needles
ELLANSÉTM is available in 4 options -S, -M, -L and -E that differ only in their duration of action. All the other product characteristics are identical for the entire product range.
CE Mark Indication
W288.02-ELLANSE Physicians Brochure_vA01.indd 5 2/02/2016 10:42 am
6
Mechanism of Action9
2-in-1 actionImmediate filling
• CMC gel provides the immediate filling & wrinkle correction
Long-lasting volumization through collagen stimulation
• PCL microspheres stimulate neocollagenesis
Before treatment1 When ELLANSÉTM is injected subcutaneously CMCgel provides immediate results
2
CMC gel is resorbed and PCL microspheres remain
3 PCL microspheres stimulate fibroblasts to produce new collagen
4
Overtime PCL microspheres are bioresorbed
5 Smooth and natural correction maintained throughout total duration of effect
6
W288.02-ELLANSE Physicians Brochure_vA01.indd 6 2/02/2016 10:42 am
7
Predictable and Controlled Total Bioresorbability10-13
Thanks to state-of-the art STATTM Technology :
• Initial length of the PCL chains is the uniquely distinguishing characteristic of ELLANSÉTM
• Varying the length of the PCL chains is the basis of the different levels of longevity options which differ from 1 to 4 years that you can adapt to your patient needs and expectations
• Fully resorbable product via hydrolysis
Microspheres size : 25-50 μm for the whole range
ELLANSÉTM provides an effect of different durations from 1 to 4 years.
At injection Chain Scission Bioresorption Total Bioresorption
At injection Chain Scission Bioresorption Total Bioresorption
2 Years
1 Year
At injection Chain Scission Bioresorption Total Bioresorption
3 Years
At injection Chain Scission Bioresorption Total Bioresorption
4 Years
ELLANSÉTM - S
ELLANSÉTM - M
ELLANSÉTM - L
ELLANSÉTM - E
PCL chainsPCL microspheres
W288.02-ELLANSE Physicians Brochure_vA01.indd 7 2/02/2016 10:42 am
8
Areas of Treatment : ELLANSÉTM range
Sustained volumizing capacity through collagen stimulation for natural and long-lasting results from 1 to 4 years, ideal for volume restoration and contour definition.
Treatment areas where ELLANSÉTM-S, -M, -L and -E can be used
NB : Glabella, lips and eyelids are not recommended for the use of ELLANSÉTM
Depth of Injection
ELLANSÉTM is indicated for sub-dermal injections. For further injection techniques please refer to the ELLANSÉTM Injection Technique Guidelines (available upon request).
Due to its cohesiveness, ELLANSÉTM is easy to shape and mold, enabling higher precision in the shaping and definition of treated areas.
SUB-DERMALTISSUE
DERMIS
EPIDERMIS
Temples and Brow Area
Malar Augmentation Cheek
Cheek
Nasolabial Folds
Jaw Line
Nose Reshaping
Marionette Lines
Chin Definition
ELLANSÉTM
W288.02-ELLANSE Physicians Brochure_vA01.indd 8 2/02/2016 10:42 am
9
13 months after ELLANSÉTM - M injection, PCL microspheres were surrounded with collagen deposition and a mild fibroblastic and histiocytic tissue response. Stainings were Haematoxylin & Eosin (A and B) and Martin-s Trichrome (C and D)
Proven Neocollagenesis induced by ELLANSÉTM
In rabbit tissue9
In human tissue14
ELLANSÉTM-M : 9 months post injection (rabbit)
Haematoxylin & Eosin staining shows :
Microspheres still round and intact during bioresorption process
Collagen fibers are stained red
ELLANSÉTM-M : 9 months post injection (rabbit)
Picro Sirius Red (PSR), Polarized light shows :
Red (arrows): collagen type I
Green (arrowheads): collagen type III
Confirmation of neocollagenesis
ELLANSÉTM-M : 21 months post injection (rabbit)
Picro Sirius Staining, Polarized light shows :
Red color confirming predominant presence of collagen type I
Type I collagen confirms stable environment and long-term efficacy
W288.02-ELLANSE Physicians Brochure_vA01.indd 9 2/02/2016 10:42 am
10
ELLANSÉTM offers clear advantages over the NASHA based dermal filler, both in terms of durability and efficiency15
Proven Efficacy & Safety
High efficacy of ELLANSÉTM - S and ELLANSÉTM - M in nasolabial folds treatment with high safety over a 2 years period10
Investigator Evaluated Aesthetic Global Improvement Scale GAIS
Comparative clinical study of ELLANSÉTM vs a NASHA hyaluronic acid for treatment of nasolabial folds15
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Patie
nts
% w
ith Im
prov
emen
t
10%
40%
55% 45%
15%
20%
45%
35%
10%
60%
10%
20%
11%
45%
11%
78%
ELLANSÉTM - S
3 6 9 12 15 18 24
months
35%
Much Improved Very Much ImprovedImproved Much Improved Very Much ImprovedImproved
12 months
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%Pa
tient
s % w
ith im
prov
emen
ts
10,0%
40,0%
0,0%
35,0%
55,0% 45,0%
15,0%
20,0%
45,0%
35,0%
10,0%
60,0%
10,0%
20,0%
24 months
11,0%
35,0%
11,0%
78,0%Pa
tient
s %
with
Im
prov
emen
t41,4%
50% 63,8% 71%
4%
58%
14%27,6%25,9%
51,7%
13,8%
5,2%
7%
31%
50%
44%
6%
58,0%
77%
23%
ELLANSÉTM - M
3,5%
3 6 9 12 15 18 24
months
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
100% 90%
Of patients with at least improved results at 12 months
100% 90%
Of patients with at least improved results at 24 months
W288.02-ELLANSE Physicians Brochure_vA01.indd 10 2/02/2016 10:42 am
11
High Safety Profile of ELLANSÉTM
The unique smooth and spherical shape of ELLANSÉTM microspheres :
• Is the basis for optimal biocompatibility as rough surfaces and irregular shaped microspheres have the propensity to induce adverse events, such as nodules, and result in decreased collagen deposition16-20
• Provide a safe, long-lasting and high quality tissue scaffold
SAFE PRODUCT COMPONENTS WITH A LONG SAFETY HISTORY
Perfectly Smooth
SEM Picture
Totally Spherical Microparticles
Light Microscopy Picture
High Quality Scaffold
Light Microscopy : Histology 2-weeks post intradermal injection
• Long-term and total bioresorption of ELLANSÉTM components through the normal metabolic pathways well documented
• PCL microspheres bioresorption demonstrated via radio-labeled bioresorption studies
LONG-TERM SAFETY : Scientific Evidence and Literature10, 13
High Patient Satisfaction10
ELLANSÉTM - S & -M : Satisfaction using Visual Analogue Scale (VAS)10
Patient Satisfaction with ELLANSÉTM Treatment (mean)
Patient SatisfactionELLANSÉTM - S
12 MonthsELLANSÉTM - M
24 Months
Satisfaction 74% 81.7%
At 24 months post-injection :
75% of patients like to repeat ELLANSÉTM - S treatment
78% of patients like to repeat ELLANSÉTM - M treatment
• Total biocompatibility demonstrated via tests according to the ISO-10993 biocompatibility standard
• 2-weeks implantation data clearly show the particles well-embedded in a healthy tissue environment and demonstrate excellent local tolerance
SHORT-TERM SAFETY : Pre-clinical Data7
• In-house in-vitro resorption study of ELLANSÉTM Range PCL microspheres consistent with published literature data
In-vitro
W288.02-ELLANSE Physicians Brochure_vA01.indd 11 2/02/2016 10:42 am
12
ELLANSÉTM Ability to Regenerate Beauty
ELLANSÉTM - S Nasolabial Folds
Before Treatment After 12 Months
Courtesy of Marion Moers-Carpi, MD, Germany
Courtesy of Marion Moers-Carpi, MD, Germany
Before Treatment After 24 Months
ELLANSÉTM - M Nasolabial Folds
Courtesy of Marion Moers-Carpi, MD, Germany
ELLANSÉTM - S Nasolabial Folds
Before Treatment After 12 Months
W288.02-ELLANSE Physicians Brochure_vA01.indd 12 2/02/2016 10:42 am
13
ELLANSÉTM - M Nose Reshaping
Before Treatment After 3 Weeks
Courtesy of Ayham Al-Ayoubi, MD, London, UK
Before Treatment After Treatment
ELLANSÉTM Cheeks and Submalar Augmentation
Courtesy of Dr. Fab Equizi, Liverpool, UK
ELLANSÉTM - M Nasolabial Folds, Cheeks and Marionette Lines
Before Treatment After 2 Months
Courtesy of Alida Harb, MD, Riyadh, Saudi-Arabia
W288.02-ELLANSE Physicians Brochure_vA01.indd 13 2/02/2016 10:42 am
14
References
1. Vleggaar D et al. Dermatological implications of skeletal ageing: a focus on supraperiosteal volumization for perioral rejuvenation. J Drugs Dermatol 2008;7:209-220.
2. Coleman SR et al. The anatomy of the ageing face: volume loss and changes in 3-dimensional topography. Aesthet Surg J 2006;26(suppl 1):S4-S9.
3. Zimbler MS et al. Anatomy and pathophysiology of facial ageing. Facial Plast Surg Clin North Am 2001;9:179-187.
4. Murphy MR et al. The ageing face consultation. In: Master Techniques in Facial Rejuvenation. Elsevier 2006;1-16.
5. Le Louarn C. Botulinum toxin and the Face Recurve® concept: decreasing resting tone and muscular regeneration. Ann Chir Plast Esth 2007;52:165-176.
6. Donofrio LM. Fat distribution: a morphologic study of the ageing face. Dermatol Surg 2000;26:1107-1111.
7. Valenga Baroni et al, Influence of aging on the quality of the skin of white women- the role of collagen. Acta cirurgica Brasileira 2012; 27: 736-740
8. CE mark-Technical dossier (Whitepaper W113.05)
9. Nicolau PJ et al. Neocollagenesis after injection of a polycaprolactone based dermal filler in a rabbit. Eur J Aesth Med Dermatol 2013;3(1):19-26.
10. Moers-Carpi MM et al. Polycaprolactone for the Correction of Nasolabial Folds: A 24-Month, Prospective, Randomized, Controlled Clinical Trial. Dermatol Surg 2013;39:457-463.
11. Pitt CG. Aliphatic polyesters II The degradation of Poly (DL-lactide), poly (ε-caprolactone), and their copolymers in vivo. Biomaterials 1981;2:215-220.
12. Varani J. Decrease collagen production in chronologically aged skin. Am J Pathol 2006;168: 1861-1868.
13. Woodruff MA et al. The return of a forgotten polymer: polycaprolactone in the 21st century. Prog Polym Sci 2010;35(10):1217-1256.
14. Kim et al. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. Journal of Cosmetic and Laser Therapy, 2014; Early Online: 1-3
15. Galadari et al. A randomized, prospective, blinded, split face, single center study comparing polycaprolactone to hyaluronic acid for treatment of nasolabial folds. The Journal of Cosmetic Dermatology
16. Laeschke K. Biocompatibility of microparticles into soft tissue fillers. Semin Cutan Med Surg 2004; 23(4):214-217.
17. Morhenn VB et al. Phagocytosis of different particulate dermal filler substances by human macrophages and skin cells. Dermatol Surg 2002;28(6):484-490.
18. Anderson JM. Mechanism of inflammation and infection with implanted devices. Cardiovasc Pathol 1993;2:33S-41S.
19. Matlage BF et al. Tissue response to implanted polymers: The significance of sample shape. J Biomed Meter Res 1976;10:391-397.
20. Nicolau PJ. Long-Lasting and permanent fillers: Biomaterials influence over host response. Plast Reconstr Surg 2007;119:2271-2286.
W288.02-ELLANSE Physicians Brochure_vA01.indd 14 2/02/2016 10:42 am
15 B&
A C
AS
ES
SINCLAIR is a pharmaceutical company with a renowned strong skin expertise:
• Provides best in class treatments in aesthetics to further support physicians in
their practice thanks to unique treatments to answer all patient needs at all
ages through minimally invasive procedures.
• Is dedicated to offering safe and effective solutions to achieve optimal results
with limited downtime.
• SINCLAIR treatments respect skin's own natural processes and contribute to
maintain the skin in good condition and to rejuvenate the face at all ages.
SINCLAIR COMMITMENT
Unique products
portfolio based on
physician and
patient needs
High quality training
program based on
physician practice
and expectations
Create added value in your daily practice
Optimize aesthetics outcome to increase
your patients satisfaction
W288.02-ELLANSE Physicians Brochure_vA01.indd 15 2/02/2016 10:42 am
SINCLAIR PHARMACEUTICALS LTD.35, Rue d’Artois, 75008 Paris, France
Tel: +33 1 53 76 11 11 Fax: +33 1 53 76 12 12www.sinclairpharma.com
www.ellanse.com
Easy to inject
Immediate correction
Sustained volumizing capacity
through collagen stimulation9
Maintained correction
Easy to mold
from 1 to 4 years
Natural results from patients
own collagen stimulation
High level of patient satisfaction10
EXCLUSIVE DISTRIBUTORFOR ELLANSÉ™
+61 3 9702 3119www.austramedex.com
W288.02-ELLANSE Physicians Brochure_vA01.indd 16 2/02/2016 10:42 am
top related